The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)
Sign Up to like & getrecommendations! Published in 2022 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-021-00932-2
Abstract: Natural killer (NK) cells have played a critical—if largely unrecognized or ignored—role in the treatment of B cell non-Hodgkin lymphoma (NHL) since the introduction of CD20-directed immunotherapy with rituximab as a cornerstone of therapy over… read more here.
Keywords: natural killer; cell nhl; hodgkin lymphoma; cell ... See more keywords
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-211623
Abstract: Background Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). It is unknown… read more here.
Keywords: lymphoma; european registries; cell nhl; treatment ... See more keywords
Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.23919
Abstract: The clinical outcome of T-cell non-Hodgkin lymphoma (NHL) is poor and innovative treatments are needed. Tenascin-C is a large extracellular glycoprotein not expressed under physiological conditions, but overexpressed in cancer. Aim of the study was… read more here.
Keywords: tenascin; cell non; cell nhl; non hodgkin ... See more keywords